201 related articles for article (PubMed ID: 33165499)
1. Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018.
DeMartino PC; Miljkovic MD; Prasad V
JAMA Intern Med; 2021 Feb; 181(2):162-167. PubMed ID: 33165499
[TBL] [Abstract][Full Text] [Related]
2. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
Benjamin DJ; Xu A; Lythgoe MP; Prasad V
JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858
[TBL] [Abstract][Full Text] [Related]
3. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
Prasad V; Mailankody S
JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020.
Haslam A; Lythgoe MP; Greenstreet Akman E; Prasad V
JAMA Netw Open; 2021 Nov; 4(11):e2135123. PubMed ID: 34792592
[TBL] [Abstract][Full Text] [Related]
5. Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval.
Sachs RE; Gavulic KA; Donohue JM; Dusetzina SB
JAMA Health Forum; 2021 Oct; 2(10):e213177. PubMed ID: 35977163
[TBL] [Abstract][Full Text] [Related]
6. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
[TBL] [Abstract][Full Text] [Related]
7. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).
Elbaz J; Haslam A; Prasad V
Cancer Med; 2024 Apr; 13(8):e7190. PubMed ID: 38659418
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
Vivot A; Jacot J; Zeitoun JD; Ravaud P; Crequit P; Porcher R
Ann Oncol; 2017 May; 28(5):1111-1116. PubMed ID: 28453694
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
11. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
Chen EY; Raghunathan V; Prasad V
JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
[TBL] [Abstract][Full Text] [Related]
12. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
Chen EY; Joshi SK; Tran A; Prasad V
JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
[TBL] [Abstract][Full Text] [Related]
13. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
Olivier T; Haslam A; Prasad V
JAMA Netw Open; 2021 Dec; 4(12):e2138793. PubMed ID: 34905002
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
15. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
16. Trends in the approval of cancer therapies by the FDA in the twenty-first century.
Scott EC; Baines AC; Gong Y; Moore R; Pamuk GE; Saber H; Subedee A; Thompson MD; Xiao W; Pazdur R; Rao VA; Schneider J; Beaver JA
Nat Rev Drug Discov; 2023 Aug; 22(8):625-640. PubMed ID: 37344568
[TBL] [Abstract][Full Text] [Related]
17. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.
Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB
JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209
[TBL] [Abstract][Full Text] [Related]
19. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
[TBL] [Abstract][Full Text] [Related]
20. Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022.
Mousavi I; Olivier T; Prasad V
JAMA Netw Open; 2022 Jun; 5(6):e2216058. PubMed ID: 35687338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
